Document:

Exhibit 10.1

		

			Exhibit 10.1

		

		

			 

		

		
			CONSULTING AGREEMENT
		

		
			    This Consulting Agreement (“Agreement”) confirms the understanding between David Schreiber (“Schreiber”) and Aspira Womens Health (“Company”) pursuant to which the Company has retained Schreiber to provide consulting services of the type described below (collectively, the “Services”), on the terms and subject to the conditions set forth herein, in connection with the matters referred to herein.
		

		
			1.    Scope of Services and Compensation
		

		
			    (a)    Schreiber agrees to perform the Services for the Company, beginning upon Schreiber’s retirement from the AWH Board on or about June 30, 2021. The Services shall be in relation to the Company’s evaluation and assessment of the feasibility of various business strategies as outlined by the Company’s CEO.  Schreiber will also perform other duties from time to time as are reasonably requested by Company and agreed to by Schreiber.
		

		
			    (b) Should the parties determine the Services should commence prior to Schreiber’s retirement from the Board, a separate agreement under the auspices of Board Compensation will be entered into with consideration consistent with this Agreement.
		

		
			    (c)    During the term of this Agreement, Schreiber will be paid $400-per hour for performing the Services.  Notwithstanding the preceding sentence, Schreiber will be paid a minimum of $80,000 for the four month period beginning on the date on which Schreiber ceases to serve on the Board (which represents compensation for 200 hours of Services). Domestic travel under 3 hours in length is booked in economy class. Travel greater than 3 hours and all International Travel is booked in First Class.
		

		
			    (d)    The Company shall make payments for Services to Schreiber promptly upon presentation of a statement of services rendered.  Schreiber will invoice the Company on a monthly basis.
		

		
			(e)    The Company shall reimburse Schreiber for his reasonable out of pocket costs, including meals, travel, lodging, parking and other expenses incurred in connection with the performance of his duties under this Agreement. Travel time is not billed for.
		

		
			2.    Period of Performance and Exclusivity
		

		
			    (a)    Unless otherwise extended by the parties, this Agreement shall run for an initial period of four (4) months from the date on which Schreiber ceases to serve on the Board (the “Initial Term”), and shall automatically renew for additional three (3) month terms unless either party provides written notice of its intent not to renew (in each case, if any, a “Renewal Term”).  The Initial Term and any Renewal Terms shall constitute the “Term”.
		

		
			    (b)    During the term of this Agreement, Schreiber shall not perform Services related to the Company’s business for any person during the term of this Agreement other than the Company, or an affiliate of the Company, without the Company’s prior written consent. 
		

		
			3.    Termination.
		

		
			        (a)    This Agreement may be terminated by either Schreiber or the Company at any time upon five (5) days prior written notice.  Upon such a termination, Schreiber shall be entitled to all accrued payments and reimbursement of expenses permissible under this Agreement and due to him on the date of termination.  In addition, if this Agreement is terminated by the Company before the conclusion of the 
		

		 

 

		Term, Schreiber shall be entitled to receive any amounts due pursuant to the minimum guaranty payment set forth in Section 1(c).
		

		
			        (b)    The parties acknowledge that the provisions of Sections 1, 4 and other provisions, which may be reasonably interpreted to be intended to do, so shall survive the expiration or termination of this Agreement. 
		

		
			4.    Indemnification.
		

		
			        The Company shall indemnify and hold harmless Schreiber from and against any and all claims, damages, losses and judgments (including reasonable attorneys’ fees and costs) arising from or related to this Agreement, except to the extent that the matter giving rise to such claim for indemnity was the result of fraud, bad faith, recklessness, willful misconduct, the commission of a felony or the gross negligence of Schreiber.
		

		
			5.    Contractual Relationship
		

		
			    In performing the services under this Agreement, Schreiber shall operate as, and have the status of, an independent contractor.  Schreiber shall not have authority to enter into any contract binding the Company or create any obligations on the part of the Company except as shall be specifically authorized by the Company.  The Company and Schreiber will be mutually responsible for determining methods for performing the services described in Section 1 hereof.
		

		
			6.    Representatives and Notices
		

		
			    All notices provided for herein shall be in writing, and may be served personally to the Fund representative or its assigns and/or a representative of Schreiber, at their respective places of business, or by registered mail to the address of each party, or may be transmitted by facsimile.
		

		
			7.    Arbitration/Jurisdiction of the Court
		

		
			    Any claim or controversy arising out of, or relating to, this agreement, or breach thereof, which is not settled between the signatories themselves, shall be settled by an independent arbitrator, mutually acceptable to both parties.  Jurisdiction for any legal action is stipulated by the parties to lie in the State of Connecticut.
		

		
			8.    Miscellaneous
		

		
			    This Agreement constitutes the entire agreement between the Company and Schreiber relating to the provisions of the Services on and after the date of this Agreement and may not be assigned without the prior written consent of the other party.  It supersedes all prior communications, representations or agreements, whether oral or written, with respect to the subject matter hereof, and has not been induced by any representations, statements or agreements other than those expressed herein.  No agreements, hereafter made between the parties shall be binding on either party unless reduced to writing and signed by an authorized officer of the party bound.  This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.  This Agreement shall be, in all respects, interpreted and construed, and the rights of the parties hereto governed, by the laws of the State of Connecticut without regard to its conflicts of laws provisions.
		

		
			[Remainder of page intentionally left blank]
		

		 

 

		
		

		
			    IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have caused this Consulting Agreement to be executed as of this 25th day of March, 2021.
		

			
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						Aspira Women’s Health

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						By:

					
					
						/s/ Valerie B. Palmieri

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						By:

					
					
						Valerie B. Palmieri

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						Title:

					
					
						President and Chief Executive Officer

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						/s/ David Schreiber

					
					
						 

					
					
						 

				
	
					
						David Schreiber

					
					
						 

					
					
						 

				

		
			﻿Exhibit
10.1

 

NOVATION
AGREEMENT

 

This
Novation Agreement (this “Agreement”)
is made as of January 30, 2021 among the University of Louisville Research Foundation, Inc. (“ULRF”), a Kentucky non-profit
corporation as the agent of the University of Louisville (“UofL”) for receiving grants and research agreements from
external funding sources and which owns and controls intellectual property on behalf of UofL, Qualigen, Therapeutics, Inc., a Delaware
corporation (“QLGN”) and Qualigen, Inc., a Delaware corporation (“Qualigen”). This Agreement is
made with respect to the Sponsored Research Agreement executed and effective on March 5, 2019, and subsequently amended on October 6,
2019 (collectively, “Sponsored Research Agreement”) by and between ULRF and Qualigen. The
parties intend this Agreement to constitute a novation of the Sponsored Research Agreement.

 

In
consideration of the following promises and other good and valuable consideration, the receipt and sufficiency of which are acknowledged,
the parties, intending to be legally bound, agree as follows:

 

1.
Assignment and Novation. Qualigen hereby grants, conveys, assigns, transfers and delivers
unto QLGN, and QLGN hereby accepts and assumes, all of Qualigen’s right, title and interest in, to and under the Sponsored Research
Agreement, as if it were the original party to the Sponsored Research Agreement in place of Qualigen. In addition, Qualigen hereby assigns,
and QLGN hereby assumes and agrees to satisfy and perform if due or when coming due as a direct obligation to ULRF, all of Qualigen’s
obligations under the Sponsored Research Agreement, regardless of whether arising before or after the Effective Date, without any further
liability to Qualigen, and ULRF agrees to look only to QLGN for satisfaction of all such obligations (collectively, the “Novation”).

 

2.
Release. ULRF hereby agrees to the Novation under this Agreement and releases and forever
discharges Qualigen from all of its obligations and liabilities under the Sponsored Research Agreement as of and from the date of this
Agreement. Qualigen hereby releases and forever discharges ULRF from all of its obligations and liabilities under the Sponsored Research
Agreement on and from the date of this Agreement.

 

3.
Substitution. ULRF recognizes QLGN as Qualigen’s successor-in-interest in and
to the Sponsored Research Agreement as of and after the date of this Agreement. ULRF and QLGN shall be bound by the terms of the Sponsored
Research Agreement in every way as if QLGN is and had always been named in the novated Sponsored Research Agreement in place of Qualigen
as a party thereto.

 

4.
General Provisions.

 

4.1
Full Force and Effect. Except as expressly set forth in this Agreement, the Sponsored Research Agreement remains unchanged and in
full force and effect.

 

4.2
Further Assurances. The parties hereby covenant and agree, without the necessity of any further consideration, to execute, acknowledge
and deliver any and all such other documents and instruments and take any such other action as may be reasonably necessary or appropriate
to carry out the intent and purposes of this Agreement.

 

    	 	 	 

     

    

 

4.3
Entire Agreement. This Agreement is the entire agreement of the parties relating to the subject matter hereof.

 

4.4
Signatories. Each individual executing this Agreement on behalf of a party hereby represents and warrants to the other parties that
he is fully and duly empowered and authorized by the first party to so execute and deliver this Agreement to the other parties on behalf
of the first party.

 

4.5
Counterparts. This Agreement may be executed and delivered in counterparts (portable document format (.pdf)/electronic transmission
included), each of which shall constitute an original document, but all of which shall constitute one and the same instrument.

 

IN
WITNESS WHEREOF, the parties have executed and delivered this Novation Agreement as of the Effective Date.

 

	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
	 	 	 
	By:	/s/
    Brennan S. Cox	 
	Name:	Brennan
    S. Cox	 
	Title:	Asst.
    Dir. – Office of Sponsored Programs	 
	 	 	 
	QUALIGEN
    THERAPEUTICS, INC.	 
	 	 	 
	By:	/s/
    Michael Poirier	 
	Name:	Michael
    Poirier	 
	Title:	President
    & CEO	 
	 	 	 
	QUALIGEN,
    INC.	 
	 	 	 
	By:	/s/
    Michael Poirier	 
	Name:	Michael
    Poirier	 
	Title:	President
    & CEO	 

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]